Treatment options and prognosis for repeatedly recurrent giant cell tumor of the spine
- 730 Downloads
Giant cell tumor of the spine has high rate of postoperative recurrence. There are not much published studies on repeatedly recurrent GCTS (RRGCTS). Also, there are controversies as to the prognostic factors and treatment options for RRGCTS.
Methods and materials
A retrospective survival analysis between 2000 and September 2014 was performed on the 74 times of in-hospital treatment of the 21 patients. Recurrence-free survival was defined as the time between the date of surgery and the date of recurrence. Factors with P values <0.05 in univariate analysis were subjected to multivariate analysis by means of proportional hazard analysis.
A total of 21 patients comprising ten males and 11 females with a mean age of 29.7 years (range 15–49) were included, with a total of 74 times of surgery performed. Eighteen patients had no evidence of disease. Univariate and multivariate analysis suggested that total spondylectomy and bisphosphonate therapy were independent prognostic factors for better RFS in RRGCTS patients.
Patients of RRGCTS are suitable for further surgical treatment with relatively good healing process and restoration of nervous function. Early diagnosis of recurrence may be associated with better prognosis. Total spondylectomy in combination with bisphosphonate therapy could reduce postoperative recurrence rate.
KeywordsRepeatedly recurrent giant cell tumor of the spine (RRGCTS) Follow-up Recurrence Prognosis
This study was supported by Shanghai youth science and technology talent sailing program (Grant 14YF1405900).
Compliance with ethical standards
Conflict of interest
The authors disclose no conflicts.
- 1.Unni KK (1996) Dahlin’s bone tumors: general aspects and data on 11,087 cases. Lippincott-Raven, New York. 5(1):234–254Google Scholar
- 6.Wei Xu, Li Xiang, Huang Wending (2013) Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center. Ann Surg Oncol 23(2):134–141Google Scholar
- 7.Takeuchi Akihiko, Tsuchiya Hiroyuki (2010) The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group. J Orthop Sci 24(4):431–441Google Scholar
- 8.Stew Fri W, Coley Badleyl (1938) Malignant giant cell tumor of bone. Am J Pathol 5(4):529–531Google Scholar
- 10.Song S, Hong JC, McDonnell SE et al (2012) Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol 23(1):654–667Google Scholar
- 12.Vult von Steyern F, Bauer HC, Trovik C, Kivioja A, Bergh P, Holmberg Jorgensen P, Follerås G, Rydholm A (2006) Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study. J Bone Jt Surg Br 5(3):1–5Google Scholar
- 15.Hart RA, Boriani S, Biagini R, Currier B, Weinstein JN (1997) A system for surgical staging and management of spine tumors. A clinical outcome study of giant cell tumors of the spine. Spine 22(17):73–82 (Phila Pa 1976) Google Scholar
- 17.Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM (2004) Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 75(7):1–7Google Scholar
- 18.Balke M (2010) Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 10(4):62Google Scholar
- 19.Zhang W, Zhang Y, Li P (2011) Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine. Spine 36(11):66–72 (Phila Pa 1976) Google Scholar
- 21.Otto S, Sotlar K, Ehrenfeld M, Pautke C (2011) Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: a case report. J Med Case Rep 5(4):77Google Scholar
- 26.Wei F, Liu X, Liu Z (2010) Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases. Spine 35(14):18–22 (Phila Pa 1976) Google Scholar
- 27.Thomas D, Henshaw R, Skubitz K (2010) Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11(2):75–80Google Scholar